In conclusion, GlaxoSmithKline's shares showed significant gains today, reflecting positive market sentiment and strong ...

With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies ...

Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs for its inhalers at $35 a month, Sen. Maggie Hassan (D-N.H.) is accusing the company of circumventing that vow through ...

GlaxoSmithKline posted rising sales yesterday – but shares slid because of fears over its vaccines division. In a boost for the pharma giant’s chief executive Emma Walmsley, turnover increased ...

The EPS is ₹ 11.38 for Q4 which increased by 52.78% Y-o-Y. Glaxosmithkline Pharmaceuticals has delivered 2.36% return in the last 1 week, 27.37% return in last 6 months and 6.55% YTD return.

AP - British drugmaker GlaxoSmithKline will pay $3 billion in fines - the largest healthcare fraud settlement in U.S. history - for criminal and civil violations involving 10 drugs that are taken ...

July 14, 2010 -- In the face of mounting evidence that GlaxoSmithKline withheld important safety data on their controversial drug Avandia, some doctors are abandoning use of this diabetes treatment.

How GlaxoSmithKline missed red flags in China By Ben Hirschler July 19, 20136:40 AM PDTUpdated July 19, 2013 ...

But GlaxoSmithKline's (GSK) chief executive, JP Garnier, believes that the group's strong product pipeline is helping it fight back. "We're able to take those hits and still move forward," he says. IC ...